Dr Nicholas Hindley
The University of Sydney
$448,112
2025 - 2028
The Research
Most cancer patients benefit from radiation therapy due to its effectiveness and low cost.
In recent years, we have found that hypofractionated treatments - where high doses are delivered over relatively few treatment sessions - improve overall survival. However, 1 in 2 lung cancer patients are ineligible for these highly effective treatments because they suffer from metastases and we currently cannot safely deliver high-dose radiation therapy to multiple independently-moving targets as patients breathe.
To double the number of patients eligible for the most effective treatments and minimise toxicity due to healthy tissue damage, we developed Voxelmap, the first method for real-time tumour and organ tracking during lung cancer radiation therapy.
To introduce Voxelmap into the clinic we have assembled an outstanding team of researchers and consumers from around the world with a proven track record of translating first-in-world technologies. With this project we hope to catalyse a paradigm shift in cancer treatment.
.svg)
